Hims & Hers Health, Inc. (NYSE:HIMS) Receives Consensus Rating of “Hold” from Brokerages

Hims & Hers Health, Inc. (NYSE:HIMS) has received an average recommendation of “Hold” from the sixteen research firms that are covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, twelve have issued a hold rating and three have given a buy rating to the company. The average 1 year price target among analysts that have covered the stock in the last year is $32.43.

A number of equities analysts recently weighed in on the company. Bank of America increased their price target on Hims & Hers Health from $30.00 to $32.00 and gave the company a “neutral” rating in a research report on Tuesday, August 11th. Barclays dropped their target price on shares of Hims & Hers Health from $39.00 to $35.00 and set an “overweight” rating on the stock in a research report on Friday, August 21st. TD Cowen boosted their price target on shares of Hims & Hers Health from $25.00 to $30.00 and gave the company a “hold” rating in a report on Tuesday, August 11th. Canaccord Genuity Group upped their price target on shares of Hims & Hers Health from $32.00 to $40.00 and gave the company a “buy” rating in a research report on Wednesday, July 1st. Finally, Wall Street Zen raised shares of Hims & Hers Health from a “sell” rating to a “hold” rating in a research note on Saturday, August 15th.

Key Hims & Hers Health News

Here are the key news stories impacting Hims & Hers Health this week:

• Positive Sentiment: Hims & Hers and Hims Australia announced new management appointments, including chief medical officers for the U.K. and Australia. The appointments could support localized clinical oversight and international growth, although the immediate financial impact is unclear. Hims & Hers Health and Hims Australia Announce Management Appointments
• Positive Sentiment: One recent analyst view upgraded Hims & Hers to a buy, citing reaccelerating U.S. revenue growth, nearly 3 million subscribers and valuation compression. The bullish case also points to the company’s long-term targets of more than $6.5 billion in revenue and $1.3 billion in adjusted EBITDA by 2030. Hims & Hers U.S. Revenue Reacceleration Is Reassuring
• Neutral Sentiment: Multiple law firms repeated notices about a securities class action covering investors who purchased HIMS securities from August 4, 2025, through July 29, 2026. The November 2, 2026 deadline is for investors seeking lead-plaintiff status; the notices themselves do not represent new lawsuits or new evidence. Kaplan Fox Hims Investor Notice
• Negative Sentiment: The legal campaign is centered on allegations that Hims & Hers made material misstatements or omissions regarding deceptive and unlawful privacy practices, as well as billing and other business conduct. The allegations have not been proven, but potential litigation costs, regulatory consequences and reputational damage are weighing on investor sentiment. Hims & Hers Faces Securities Class Action

Insiders Place Their Bets

In other news, insider Deborah Autor sold 16,773 shares of Hims & Hers Health stock in a transaction on Tuesday, August 18th. The stock was sold at an average price of $27.85, for a total transaction of $467,128.05. Following the transaction, the insider owned 48,961 shares in the company, valued at approximately $1,363,563.85. The trade was a 25.52% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, COO Michael Chi sold 14,027 shares of the company’s stock in a transaction on Tuesday, September 15th. The shares were sold at an average price of $28.39, for a total value of $398,226.53. Following the transaction, the chief operating officer directly owned 456,660 shares in the company, valued at $12,964,577.40. The trade was a 2.98% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 128,684 shares of company stock worth $3,731,869. 11.76% of the stock is currently owned by corporate insiders.

Institutional Trading of Hims & Hers Health

Institutional investors have recently made changes to their positions in the stock. Versant Capital Management Inc lifted its position in Hims & Hers Health by 801.2% in the 2nd quarter. Versant Capital Management Inc now owns 748 shares of the company’s stock worth $26,000 after buying an additional 665 shares in the last quarter. MassMutual Private Wealth & Trust FSB grew its holdings in shares of Hims & Hers Health by 70.0% during the 2nd quarter. MassMutual Private Wealth & Trust FSB now owns 775 shares of the company’s stock valued at $27,000 after acquiring an additional 319 shares in the last quarter. Compass Financial Management LLC purchased a new position in shares of Hims & Hers Health during the 2nd quarter valued at $50,000. Bogart Wealth LLC increased its stake in shares of Hims & Hers Health by 180.7% in the first quarter. Bogart Wealth LLC now owns 2,526 shares of the company’s stock worth $52,000 after acquiring an additional 1,626 shares during the last quarter. Finally, Eurizon Capital SGR S.p.A. acquired a new position in shares of Hims & Hers Health in the fourth quarter worth $59,000. 63.52% of the stock is currently owned by institutional investors and hedge funds.

Hims & Hers Health Stock Down 1.7%

HIMS stock opened at $29.27 on Friday. The firm has a market cap of $6.83 billion, a PE ratio of -46.46 and a beta of 2.44. Hims & Hers Health has a 12 month low of $13.74 and a 12 month high of $65.30. The company has a debt-to-equity ratio of 4.21, a current ratio of 0.93 and a quick ratio of 0.87. The firm has a 50 day simple moving average of $29.27 and a 200 day simple moving average of $28.24.

Hims & Hers Health (NYSE:HIMS) last posted its quarterly earnings results on Monday, August 10th. The company reported ($0.37) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.05) by ($0.32). The business had revenue of $753.21 million during the quarter, compared to analyst estimates of $698.90 million. Hims & Hers Health had a negative return on equity of 6.51% and a negative net margin of 5.51%.The company’s quarterly revenue was up 38.2% compared to the same quarter last year. During the same quarter last year, the firm posted $0.17 EPS. Equities research analysts forecast that Hims & Hers Health will post -0.16 earnings per share for the current fiscal year.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc is a direct-to-consumer telehealth company that provides access to personalized healthcare through its online platforms, Hims and Hers. The company connects consumers with licensed healthcare professionals for virtual consultations, treatment plans and prescription medications where appropriate.

Its services address a range of common health and wellness needs, including sexual health, hair loss, skincare, mental health, weight management and primary care. Hims & Hers offers branded and generic treatments, over-the-counter products, supplements and personal-care products, with services designed for both men and women.

The company was founded in 2016, launched the Hims brand in 2017 and introduced the Hers brand in 2018.